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Frameshift mutations of coding mononucleotide repeat of the hRAD50 gene and formation of the mutant
hMRE11 splicing variant are frequent events in tumors with mismatch repair (MMR) deficiency. Both the
hRAD50 and hMRE11 proteins form a heterotrimer with the NBS1, and this heterotrimer is involved in the double
strand DNA break repair by homologous recombination and nonhomologous end-joining (NHEJ). In order to
clarify the role of hRAD50 and hMRE11 gene alterations in MMR-deficient tumors, we analyzed the expression of
the hRAD50 and hMRE11 proteins and we evaluated NHEJ in the seven MMR-deficient and five MMR-proficient
colon cancer cell lines. Frameshift mutations of the hRAD50 gene were found in five of seven MMR-deficient cell
lines, and this was directly related to the decreased expression of hRAD50 mRNA and protein. The mutant
hMRE11 splicing variant was found in all of the seven MMR-deficient cell lines, and this was related to the
decreased hMRE11 expression in four of the seven MMR-deficient cell lines. MMR-deficient cell lines with
decreased hRAD50 and hMRE11 expressions were more sensitive to c-irradiation, and these cell lines showed
an impaired NHEJ. The impairment of NHEJ was induced after knockdown of hRAD50 and hMRE11 through
small interference RNA. Our findings suggest that mutations of hRAD50 and hMRE11 genes in MMR-deficient
tumors are related to the defects in NHEJ, and this may result in chromosomal changes during the progression
of tumor.
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Recent molecular genetic studies have revealed
that there is a subset of carcinoma that develops
from a deficiency of the DNA mismatch repair
(MMR) system.1 This genetic pathway, the micro-
satellite instability (MSI) pathway, begins with
the inactivation of one of a group of genes that
is responsible for DNA nucleotide MMR, and this
leads to extensive mutations in both the repetitive
and nonrepetitive DNA sequences with a low
frequency of allelic losses, and rare alterations of
tumor DNA content have also been noted.2,3 The
mechanism of tumorigenesis in these high micro-
satellite instability (MSI-H) tumors is thought to
involve the frameshift mutations of microsatellite
repeats within the coding regions of the affected
target genes, and the inactivation of these target
genes is believed to directly contribute to the
development and progression of tumor.
Among the target genes of the MSI-H carcinomas,
some of the genes involved in DNA repair are
known to be frequently mutated. Frequent frame-
shift mutations of the coding nucleotide repeat of
the hRAD50 gene, and frequent mutations of
the microsatellite of the hMRE11 gene and the
formation of splicing variants have recently been
reported in MMR-deficient tumors.4,5 This mutation
of the hMRE11 gene leads to the skipping of exon 5,
and to the introduction of a premature stop codon
in the assembly of a mutant hMRE11 transcript;
this mutant hMRE11 transcript thereafter has
been referred to as the 484del88 transcript. Both
the hRAD50 and hMRE11 proteins form a hetero-
trimer with the NBS1 protein, and this heterotrimer
is involved in double strand DNA break repair
by homologous recombination and nonhomo-
logous end-joining (NHEJ).6 The role of this MRN
complex in DNA damage signaling and chromosome
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instability had been previously reported on.5,7 We
have recently found that MMR-deficient tumors
with the hRAD50 frameshift mutation have more
chromosomal aberrations than those of MMR-defi-
cient tumors without the hRAD50 mutation, and
this suggests that chromosomal instability in MSI-H
colorectal carcinomas might be induced from the
functional alterations of the MRN complex.8
In order to clarify the role of hRAD50 and hMRE11
gene alterations in MMR-deficient tumors, we
analyzed the relationship between the mutation
and the expression status of the MRN complexes,
and we measured the DNA repair activities by
evaluating NHEJ in the seven MMR-deficient
colon cancer cell lines. Our findings suggest
that impaired expression of the hRAD50 and
hMRE11 proteins is directly related to the mutation
status of each gene and the decreased DNA repair
activity of NHEJ.
Materials and methods
Cell Culture and Cell-Free Extracts Preparation
The 12 cell lines we used were obtained from either
the American Type Culture Collection (ATCC;
http://www.atcc.org) or the Korean Cell Line Bank
(KCLB; http://cellbank.snu.ac.kr). In all, 10 of the
colon cell lines, LS174T, SNUC2A, SNUC4,
HCT116, Lovo, HCT8, DLD-1, SW480, COLO201
and COLO205 were grown in RPMI medium
supplemented with 10% fetal bovine serum (Life
Technologies, Inc., Grand Island, NY, USA),
100 units/ml penicillin and 100 mg/ml streptomycin
at 371C in the presence of 5% CO2. The other two
cell lines, WIDR and HT29, were cultured in
Dulbecco’s modified Eagle’s medium supplemented
with 10% fetal bovine serum (Life Technologies)
and antibiotics (100 units/ml penicillin and 100 mg/
ml streptomycin). All the cell extracts were pre-
pared by homogenization of cells that were first
swollen in hypotonic buffer as described pre-
viously.9
Screening of MSI
We used seven (LS174T, SNUC2A, SNUC4, HCT116,
Lovo, HCT8 and DLD-1) of the 12 cell lines that were
previously reported as being MMR-deficient, and we
also used the remaining five cell lines (SW480,
HT29, COLO201, COLO205 and WIDR) that were
previously reported as being MMR-proficient in
terms of their MSI status, as determined by previous
studies.10–12 The DNAs from these 12 colon cancer
cell lines were PCR amplified at three microsatellite
loci (BAT25, BAT26 and BAT40) to evaluate the
MSI. PCR reactions, separation of PCR products and
MSI interpretation were performed as described
previously.4,13
Detection of Frameshift Mutation
We analyzed the status of frameshift mutations
of the hRAD50 and hMRE11 genes as described
previously.4,5,13 DNA preparation and mutation
analysis of the two target genes were performed
as described previously. All of the PCR products
of these genes showed as one band from the normal
DNA, whereas monoallelic or biallelic mutations
were detected in some MSI-H tumors (Figures 1
and 2).
Analysis of hRAD50, hMRE11 and NBS1 Expression,
and Immunoprecipitation
For semiquantitative RT-PCR, the RNA (1 mg) was
reversed transcribed using M-MLV reverse transcrip-
tase (Invitrogen, San Diego, CA, USA) according
to the manufacturer’s instructions. For each gene,
the sequences of the forward and reverse primers
were as follows: hRAD50, NM_005732 (Gene
Bank accession number), 50-AACTGCGACTTGCTCCA
GAT-30, 50-CAATTATGCTTTGCCTCATGG-30; hMRE11,
NM_005591, 50-AATATTTTGGAGGAGAATCTTAG
GG-30, 50-ATTGAAATGTTGAGGTTGCC-30;5 b-actin,
NM_001101, 50-TGCTATCCCTGTACGCCTCT-30, 50-
GTACTTGCGCTCAGGAGGAG-30. b-Actin was used
as an internal control. For the Western blot analysis,
20 mg of each protein lysate was separated on 6%
SDS-PAGE; this was then blotted onto a polyviny-
lidene difluoride membrane (Amersham Bios-
ciences) and next probed with the antibodies to
hRAD50 (C-19, polyclonal; Santa Cruz, CA, USA
and monoclonal Ab 13B3, Gene Tex. Inc.), hMRE11
(polyclonal; BD Biosciences, Franklin Lakes, NJ,
USA), and glyceraldehyde-3-phosphate dehydro-
genase (G3PDH; polyclonal; Trevigen, Gaithersburg,
MD, USA). The reactions were then developed with
ECL-Plus (Amersham Pharmacia Biotech). For im-
munoprecipitation, the cell lysates (450 mg) were
precleared and then gently rocked on an orbital
shaker with an immunoprecipitating antibody, Nbs1
(Anti-Nibrin/Nbs1; polycolonal; Upstate) at 41C.
The immune complexes were collected by centrifu-
gation and then boiled to dissociate the immuno-
complexes from the beads. The beads were collected
by centrifugation and protein separation was per-
formed on the supernatant fraction by SDS-PAGE.
To compare the relative binding of hRAD50 and
hMRE11 with NBS1, NBS1 was corrected equally.
Cell Survival Assay
The survival curves for the cell lines were obtained
by colony-forming assays. The cells were trypsi-
nized and diluted to form a single-cell suspension
that was irradiated (at 0, 2, 4 and 6 Gy) using a 137
cesium g-irradiation source (Gammacell 3000 Elan,
MDS Nordion, Ontario, Canada). After irradiation,
the cells were diluted so that the appropriate
Impaired nonhomologous end-joining in mismatch-deficient tumors
KH Koh et al
1131
Laboratory Investigation (2005) 85, 1130–1138
numbers of cells were seeded into 60 mm culture
dishes; the cells were grown for 14 days, then they
were fixed and stained with a 70% ethanol solution
and 1% crystal violet. Colonies containing 4B50
cells were scored. The percentage of cell survival
was determined relative to numbers of colonies from
the untreated cells. Each experiment was performed
three times for each radiation. The software used for
a statistical analysis was the Prism 4.0 (GraphPad
Software, San Diego, CA, USA).
Small Interfering RNA Transfection
hRAD50 and hMRE11 expressions were knocked
down by transfection with an siRNA duplex using
Silencert siRNA Construction kit (Ambion Inc.,
Austin, TX, USA). Targeted nucleotides were as
follows: hRAD50, 50-GCGACTTGCT-CCAGATAAA-
30; hMRE11, 50-AAATCACTTTGGACGTTCA-30;
Luciferase (as control); 50-CGTACGCGGAATACTTC
GA-30. Small interfering RNA (siRNA) using lipo-
fectaminet 2000 (Invitrogen) was transfected to
SW480 and HCT116 cells with 100 pmol/6 105
according to the manufacturer’s protocol in six-well
plate. To obtain proteins in NHEJ assay of SW480
and HCT116 transfected with siRNA, scales up to
100 mm culture dishes were performed with the
same concentrations of siRNA. All the experiments
were carried out 48 h after transfection, correspond-
ing to 40–50% confluency of cell lines at the time of
siRNA transfection.
Preparation of Substrate DNA and Analysis of NHEJ
Activity
We designed and made the substrate DNA for the
end-joining assay that generated a linear dimer as a
reaction product without the formation of circular
monomers or multimers. First, 2 mg of pBluescript
KS(þ ) were digested with BamHI and then this was
labeled with [a-32P]dCTP by a Klenow fill-in reac-
tion using dATP, dTTP, dGTP and [a-32P]dCTP for
the blunt end formation. After the filling reaction,
the Klenow enzyme was inactivated by incubating
the reaction mixture at 721C for 15 min. To generate
the inert ends that cannot participate in the end-
joining reaction, the 50 phosphate groups of the DNA
were removed by a treatment with 10 units of calf
intestinal alkaline phosphatase (Promega) for 1 h at
371C. After purification of the treated plasmid DNA
Figure 1 Mutation status of the hRAD50 gene in seven MMR-deficient and five MMR-proficient colorectal carcinoma cell lines (a). Five
(LS174T, SNUC2A, SNUC4, HCT116 and Lovo) out of the seven MMR-deficient colon cell lines showed frameshift mutations (m) at the
coding nucleotide repeats of the hRAD50 gene. All the mutations were heterozygous; the LS174T cell line showed one base pair insertion
and the other four cell lines (SNUC2A, SNUC4, HCT116 and Lovo) showed one base pair deletion. Expression of hRAD50 mRNA and
protein in the seven MMR-deficient and five MMR-proficient cell lines (b and c). The five MMR-deficient cell lines having the hRAD50
mutation demonstrated the decreased expression of hRAD50 mRNA and protein.
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by using a gel extraction kit (Qiagen, Valencia, CA,
USA), one of two dephosphorylated ends of the
DNA was removed by digestion using EcoRI. The
DNA was purified again, and it was then used as a
substrate for the final end-joining assay. End-joining
assays in the crude cell extracts were carried out as
previously described.9 The whole-cell extracts were
normalized for their respective total protein levels
using the Bio-Rad protein assay (Bio-Rad, Rich-
mond, CA, USA). Reactions (20 ml) were then carried
out in 50 mM triethanolamine-HCl (pH 7.5), 0.5 mM
Mg(OAc)2, 60 mM potassium acetate, 2 mM ATP,
1 mM DTT and 0.1 mg/ml BSA. The cell-free extracts
were incubated for 5 min at 371C before the addition
of 20 ng [a-32P]dCTP labeled DNA. Positive control
joining by T4 ligase (New England Biolabs) was
performed using the manufacturer’s recommended
buffer. The samples were incubated at 371C for 2 h
with the [a-32P]dCTP labeled DNA product, and then
the samples were deproteinized by proteinase K
(2 mg/ml) and 0.5% (v/w) SDS at 371C for 15 min.
The purified DNA substrate was analyzed by
electrophoresis on 0.7% agarose gels, and this was
followed by autoradiography. The quantitation of
DNA end-joining efficiency was carried out by
densitometry.
Results
Frequent Mutation and the Decreased Expression of
hRAD50 in MMR-Deficient Colon Cancer Cell Lines
We found frameshift mutations of the hRAD50
gene in five of the seven MMR-deficient cell lines.
No frameshift mutations of the hRAD50 gene
were found in the five MMR-proficient cell lines
(Table 1). All the mutations were heterozygous; the
LS174T cell line showed one base pair insertion,
and the other four cell lines (SNUC2A, SNUC4,
HCT116 and Lovo) showed one base pair deletion
Figure 2 Mutation status of poly T (11) repeats of the hMRE11 gene and the formation of splicing variants of hMRE11 mRNA in the seven
MMR-deficient and five MMR-proficient cell lines (a and b). All of the seven MMR-deficient cell lines showed frameshift mutations of
the poly T (11) repeat, and no mutation was found in five MMR-proficient cell lines. Spicing variants of the hMRE11 mRNA were
detected in all of MMR-deficient cell lines and in one (HT29) MMR-proficient cell lines. Note that four out of seven MMR-deficient cell
lines showed the splicing variant mRNA of the hMRE11 gene and the decreased expression of wild-type hMRE11 mRNA. Expression of
hMRE11 protein in seven MMR-deficient cell lines and in five MMR-proficient cell lines (c). The protein expression of the hMRE11 gene
was correlated to the wild-type mRNA of the hMRE11 gene expression; thus, four cell lines (LS174T, SNUC2A, SNUC4 and HCT116)
demonstrated a markedly decreased expression of the hMRE11 protein.
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(Table 1 and Figure 1a). The expression of hRAD50
mRNA was directly related to the mutation status;
all of the five MMR-deficient cell lines with the
hRAD50 frameshift mutation showed decreased
mRNA expression compared to the two MMR-
deficient cell lines that were lacking the hRAD50
frameshift mutation, and also compared to the five
MMR-proficient cell lines (Figure 1b). The hRAD50
protein expressions, as determined by Western
blotting, were directly related to the amount
of hRAD50 mRNA expression. The amount of
hRAD50 mRNA and protein in these five MMR-
deficient cell lines with the hRAD50 frameshift
mutation was approximately half to that observed
for the other cell lines, as was demonstrated by
densitometric analysis.
Formation of the Splicing Variant and the Decreased
Expression of hMRE11 in MMR-Deficient Colon
Cancer Cell Lines
We analyzed the status of MSI in the poly-T (11)
repeats that are located within intervening sequence
4 (IVS- 4), and they were previously reported to be
related to the splicing variant formation.5 As we
expected, we found frameshift mutations in all of
the seven MMR-deficient cell lines, and we found
no mutations in the five MMR-proficient cell lines
(Table 1 and Figure 2a). We also found the splicing
variant form of mRNA for the hMRE11 gene in all
of the seven MMR-deficient cell lines and in
one MMR-proficient cell line, HT29 (Figure 2b).
The amount of wild-type mRNA and protein
expression of hMRE11 gene was variable, but
cell lines with biallelic mutations showed markedly
decreased mRNA and protein expression of
hMRE11; four of the 7 MMR-deficient cell lines
demonstrated a decreased amount of wild-type
mRNA and protein for the hMRE11 gene compared
to other three MMR-deficient and five MMR-profi-
cient cell lines (Figure 2c).
MRN Complex Formation is Decreased in the Colon
Cancer Cell Lines with the hRAD50 Mutation
Since the hRAD50 and hMRE11 proteins form a
heterotrimer with the NBS1 protein, and the MRN
complex is involved in the double strand DNA break
repair, we evaluated the amount of the MRN
complex by immunoprecipitation (IP). We used the
NBS1 antibody for IP, and we evaluated the expres-
sion level of hRAD50 and hMRE11 protein com-
pared with the relative amount of NBS1 protein. The
amount of MRN complex was markedly decreased
in the five colon cancer cell lines with the hRAD50
mutation. These findings indicate that the decreased
hRAD50 protein expression of MMR-deficient cell
lines with the hRAD50 mutation is the cause of the
decreased MRN complex formation (Figure 3).
Sensitivity of Colon Cancer Cell Lines to c-Irradiation
We evaluated the sensitivity of tumor cell lines to g-
irradiation by using a colony-forming assay (Figure
4). After g-irradiation, the five MMR-deficient cell
lines displayed worse survival than the three MMR-
proficient and two MMR-deficient cell lines. At 2 Gy
g-irradiation, MMR-proficient cell lines had a survi-
val rate greater than 55%, whereas the survival rates
of the five MMR-deficient cell lines (LS174T,
SNUC2A, SNUC4, HCT116 and Lovo) were below
37%. Among MMR-deficient cell lines, DLD-1 and
HCT8 were less sensitive to g-irradiation (their
survival was 7.1 and 10%, respectively) compared
to a 0% survival rate for the rest of the five MMR-
deficient cell lines at the maximum dose of irradia-
tion, 6 Gy. Our data suggest that g-irradiation
sensitivity is related to the expression status of
Table 1 Microsatellite instability, and mutation status of the coding mononucleotide repeats of the hRAD50, TGF-b RII, BAX in 12 colon
cancer cell lines
Cell lines MSI status BAT26 MRE11 Frameshift mutation of CMR in
hMSH2 ploy(A)26 poly(T)11 intron 4 hRAD50 TGF-b RII BAX
LS174T MSI + 1/2 +1/w 1/1 1/1
SNUC2A MSI + 1/2 1/w w/w w/w
SNUC4 MSI + 1/2 1/w 1/1 1/w
HCT116 MSI + 1/2 1/w 1/1 1/w
Lovo MSI + 1/1 1/w 1/2 +1/1
HCT8 MSI + 2/w w/w 1/w w/w
DLD-1 MSI + 2/w w/w 1/w w/w
SW480 MSS  w/w w/w w/w w/w
HT29 MSS  w/w w/w w/w w/w
Colo201 MSS  w/w w/w w/w w/w
Colo205 MSS  w/w w/w w/w w/w
WIDR MSS  w/w w/w w/w w/w
MSI, microsatellite instability; MSS, microsatellite stability; w, wild type; CMR, the coding mononucleotide repeats.
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hRAD50 and hMRE11 expression. The five MMR-
deficient cell lines showed a high sensitivity along
with the decreased hRAD50 and hMRE11 expres-
sion. In contrast, the remaining two MMR-deficient
cell lines (DLD-1 and HCT8) showed normal
hRAD50, hMRE11 expression was slightly higher
than the five MMR-deficient cell lines, and their
sensitivity was not different from the three MMR-
proficient cell lines.
NHEJ is Decreased in MMR-Deficient Colon Cancer
Cell Lines
We considered the possibility that the impaired
expression of the hRAD50 and hMRE11 could result
in the abnormal function of the DNA repair
mechanism, as related to NHEJ. We measured the
end-joining activity in all the 12 human colon
cancer cell lines. We used the HeLa cell line as a
control for the comparative joining effect. The
extracts from MMR-proficient cell lines were more
efficient at joining DNA substrates than the extracts
from MMR-deficient cell lines. When we checked
NHEJ effect through the end-joining assay by
densitometric analysis in the seven MMR-deficient
cell lines, the four cell lines having a decreased
hRAD50 expression showed a more decreased NHEJ
activity than the two MMR-deficient cell lines
having a normal hRAD50 expression (Figure 5).
Unlike other four cell lines, one MMR-deficient cell
line with decreased hRAD50 expression, HCT116,
showed slightly decreased NHEJ activity. To clarify
the association between the expression level of
the hRAD50 and hMRE11 and NHEJ activity, we
performed an siRNA knockdown of the target genes,
hRAD50 and hMRE11. siRNA for hRAD50 and
hMRE11 was transfected to SW480 , a cell line with
normal expression of the MRN complex, and
HCT116, a cell line with a decreased hRAD50
and hMRE11. Both cell lines showed a knockdown
of hRAD50 and hMRE11 after an siRNA transfection
study (Figure 6a). NHEJ activity was decreased
according to the decreased level of hRAD50 and
hMRE11 in both cell lines (Figure 6b). HCT116
with a mutant type of hRAD50 and hMRE11 gene
showed a lower end-joining capacity after siRNA
treatment than the untreated case. The NHEJ activity
of untreated cases of SW480 and HCT116 cells
were the same as Figure 5. Our data suggest that
the difference of the end-joining effect between
Figure 3 Formation affinity of the MRN complex in the 12 colon
cell lines. Nibrin (NBS1) was immunoprecipitated (IP) from
450mg of total proteins per each cell line using a polyclonal anti-
nibrin antibody, and the immunoprecipitates were then separated
on 8% SDS-polyacrylamide gels. The gels were Western-blotted
and probed with an anti-nibrin antibody. Blots were stripped and
reprobed with an anti-Rad50 antibody and, then with an anti-
hMRE11 antibody (a). Quantitation of RAD50 and hMRE11
protein in individual cell lines relative to total nibrin protein
was performed by densitometry (Tina; Raytest Isotopenmegera¨te
GmbH). (b) MRN complex forming affinity of hRAD50 and
hMRE11. Binding of NBS1 protein to form hRAD50/NBS1 and
hMRE11/NBS1 was lower in the five MMR-deficient cell lines
than in the two MMR-deficient and five MMR-proficient cell
lines.
Figure 4 Sensitivity of the tumor cell lines to g-irradiation. The
cell survival curves for nine colon cell lines were obtained after
exposure of 0, 2, 4 and 6 Gy from a g-ray source. MMR-proficient
cell lines (SW480, HT-29 and WIDR) are shown with the dotted
lines and MMR-deficient cell lines (LS174T, SNUC2A, SNUC4,
HCT116, Lovo, HCT8 and DLD-1) are shown with the solid lines.
MMR-deficient cell lines with decreased hRAD50 and hMRE11
expression showed an increased sensitivity to the g-irradiation,
more than did the two MMR-deficient cell lines with normal
hRAD50 and hMRE11 expression and also more than the three
MMR-proficient cell lines.
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MMR-deficient cell lines and MMR-proficient cell
lines was related to the mutation and the impaired
expression status of the hRAD50 and hMRE11 genes.
Discussion
In this study, we have demonstrated that the
expression of hRAD50 and/or hMRE11 is impaired
in MMR-deficient cell lines having the hRAD50
and/or hMRE11 mutations. Our finding suggested
that there was a relationship between the expression
of the hRAD50 and hMRE11 genes in MMR-deficient
cell lines and the decreased NHEJ activity. These
findings suggest that DNA repair performed through
NHEJ system is frequently impaired in MMR-
deficient tumors, and this might result in additional
chromosomal changes and in the increased sensi-
tivity of MMR-deficient tumors to g-irradiation.
Genomic instability is one of the hallmarks of
carcinomas.14,15 Recent molecular genetic studies
have revealed that the molecular genetics of human
cancers can be categorized into two major types of
genomic instabilities: chromosomal instability (CIN)
and MSI. CIN is thought to be caused by continuous
losses and gains in the chromosomes during mitosis,
and this is characterized by a high frequency of
allelic losses, deletions and/or mutations of the
tumor suppressor genes. Mutations in the cell-cycle
regulators, checkpoint proteins and structural com-
ponents of the mitotic spindle can be a cause of
CIN.16,17 The other pathway for genomic instability
is the MSI pathway, and it begins with the inactiva-
tion of one of a group of genes responsible for DNA
nucleotide MMR. The mechanism of tumorigenesis
in MSI-H tumors is thought to involve frameshift
mutations of microsatellite repeats within the cod-
ing regions of the affected target genes, and the
inactivation of these target genes is believed to
directly contribute to the development and progres-
sion of tumor. The reported target genes of MSI-H
tumors can be functionally categorized as tumor
suppressors and those genes that are involved in
apoptosis and DNA repair.18 Many genes involved in
DNA damage signaling and in the DNA repair
pathways play critical roles in the suppression of
genome instabilities. We and other researchers have
reported observing frequent inactivating mutations
of the hRAD50 and hMRE11 genes in MMR-deficient
tumors.4,5,19 In this study, we confirmed that the
mutations of the hRAD50 and hMRE11 genes were
frequently observed in MMR-deficient cell lines.
The inactivating mutation of the hRAD50 gene and
the formation of the inactive hMRE11 splicing
variant in MMR-deficient tumors can cause struc-
tural chromosomal changes and so result in addi-
tional chromosomal instability in MMR-deficient
tumors. We have previously reported on the in-
creased chromosome aberrations in MSI-H colon
cancers having the hRAD50 mutation.8 Therefore,
we hypothesized that changes of the DNA repair
genes in MMR-deficient tumors might be a link
between the CIN and MSI pathways, and so we
examined the biological significance of these
changes in MMR-deficient tumors.
We suggested an impaired expression of the
hRAD50 and/or hMRE11 proteins in MMR-deficient
tumors, and this impaired expression is related to
the mutation status of the hRAD50 and hMRE11
genes in MMR-deficient tumors. All of MMR-
deficient tumors with hRAD50 mutations that we
observed were heterozygous. Therefore, the effect of
the hRAD50 mutation was a haploinsufficiency
because the amount of wild-type hRAD50 mRNA
in MMR-deficient tumors with the hRAD50 muta-
tion was approximately half of that compared to the
tumors without the hRAD50 mutation. The amount
of hMRE11 expression was variable in MMR-
deficient tumors. We found monoallelic and bialle-
lic mutations in the poly-T (11) repeat of the
hMRE11 gene and in the formation of splicing
variants in all of the seven MMR-deficient tumors.
By RT-PCR analysis, the amount of the wild-type
hMRE11 mRNA and the amount of mRNA from the
splicing variants were shown to be variable. For the
Figure 5 (a) Measurement of NHEJ activities by DNA end-joining
assay in the seven MMR-deficient cell lines and the five proficient
cell lines. NHEJ activities of MMR-deficient cell lines are
decreased more than that of MMR-proficient cell lines. (b)
Especially, the four MMR-deficient cell lines (LS174T, SNUC2A,
SNUC4 and Lovo) having a decreased hRAD50 expression
showed a more decreased NHEJ activity than did the two MMR-
deficient cell lines(HCT8, DLD-1) with normal hRAD50 expres-
sion by a bar graph. Positive and Negative C is the positive and
negative control. The HeLa cell line is used as a control for the
comparative end-joining effect.
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four MMR-deficient cell lines with biallelic muta-
tions, the wild-type mRNA was certainly under-
expressed and this was closely related to the
markedly decreased expression of the hMRE11
protein. In these cell lines, formation of the MRN
complex and its function might be more damaged
because these four MMR-deficient cell lines also had
hRAD50 and hMRE11 mutations and these cells
showed decreased hRAD50 and hMRE11 protein
expressions. These impaired expressions of hRAD50
and hMRE11 proteins were expected to result in
defective DNA repair and increased genetic instabil-
ity, and this would lead to somatic mutations in
other tumor suppressor genes and in the onco-
genes.20
We found that the impaired expression of the
hRAD50 and/or hMRE11 proteins in MMR-deficient
tumors resulted in the decreased MRN complex
formation and this was related to the increased
sensitivity to g-irradiation and the decreased NHEJ.
DNA damage signaling and double-stranded DNA
break (DSB) repair are included as important parts of
a large pool of biological processes that are crucial to
maintaining genomic stability. These DSBs are
repaired by two main pathways: homologous re-
combination (HR) and NHEJ. HR is mainly mediated
through the replication protein A (RPA), RAD51,
RAD52, RAD54, several RAD51 PARALOGUES, the
MRN complex and the BRCA proteins.21 Proteins
involved in NHEJ are the KU heterodimer (KU70,
KU80), DNA-dependent protein kinase (DNA-PKcs),
DNA ligase IV, XRCC4 and the MRN complex.22 The
MRN complex has a significant function altogether
among the major components involved in the HR
and NHEJ pathways, and these pathways are not
mutually exclusive. Mutations in the components of
the MRN complex result in DNA-damage sensitivity,
genomic instability, telomere shortening and aber-
rant meiosis. In this study, we found higher
sensitivity to g-irradiation in MMR-deficient cell
lines that had decreased hRAD50 and hMRE11
proteins expression. In contrast, the two MMR-
deficient cell lines with normal MRN complex
formation showed sensitivity that was similar to
MMR-proficient cell lines after g-irradiation. A
similar high sensitivity to the DNA DSB producing
Figure 6 DNA NHEJ activities in HCT116 and SW480 cell lines after a knockdown of hRAD50 and hMRE11 through small interfering
RNA (siRNA). SW480 cell line has a wild-type phenotype of hRAD50 and hMRE11, while an HCT116 cell line has a mutant type
phenotype of hRAD50 and hMRE11. Immunoblot analysis demonstrated that the target proteins, hRAD50 and hMRE11, were knocked
down in both cell lines (a). Decreased end-joining activity was noted in the cell line treated with an siRNA of hRAD50 and hMRE11 (b).
U represents an untreated sample used as a control.
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drug, Bleomycin, had also been reported for
MMR-deficient cell lines.23 The relationship be-
tween the mutation within the components of
the MRN complex and a genetic disease is also
well known. Hypomorphic mutations of the
hMRE11 gene cause an ataxia-telangiectasia-like
disease (ATLD), and NBS1 gene mutations cause
the Nijmegen breakage syndrome (NBS). A mutation
in the RAD50 gene has recently been described in a
patient with NBS.24 Defects for both DSB pathways
might result in enhanced chromosomal aberra-
tions.25 A defect of HR repair in MMR-deficient
tumor cell lines has been reported.26 In this study,
we suggest a relationship between impaired NHEJ
function and the decreased hRAD50 and/or hMRE11
gene expression. Based on these findings, it can be
suggested that mutations of the hRAD50 and
hMRE11 genes in MMR-deficient tumors are related
to the defects in NHEJ system, and this may result in
chromosomal changes during the progression of
tumor.
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